News

CLINUVEL
Posted by CLINUVEL
January 17, 2022

CLINUVEL completes enrolment in world-first stroke study

CLINUVEL today announced that it has completed enrolment in its world-first study...

Read More
CLINUVEL
Posted by CLINUVEL
January 10, 2022

CLINUVEL’S GROWTH AND EXPANSION - H.C. Wainwright Bioconnect Conference 2022

CLINUVEL's Head of Investor Relations, Malcolm Bull, presents to the H.C. Wainwright...

Read More
CLINUVEL
Posted by CLINUVEL
December 23, 2021

Progress of CLINUVEL’s DNA Repair Program

CLINUVEL PHARMACEUTICALS LTD today announced that two xeroderma pigmentosum (XP) patients have...

Read More
CLINUVEL
Posted by CLINUVEL
December 21, 2021

Chair's Letter to Shareholders

On behalf of the Board, thank you to those shareholders who chose...

Read More
CLINUVEL
Posted by CLINUVEL
December 21, 2021

CLINUVEL Kommuniqué VI

Der letzte Monat war eine tragische Lektion in Bezug auf die Herausforderungen...

Read More
CLINUVEL.
Posted by CLINUVEL.
December 20, 2021

SCENESSE® as Vitiligo Monotherapy

CLINUVEL’s drug SCENESSE® (afamelanotide 16mg) will be evaluated as a monotherapy in...

Read More
CLINUVEL
Posted by CLINUVEL
December 20, 2021

Vitiligo Communiqué IV

CLINUVEL’s fourth Vitiligo Communiqué discusses the long-term consequences, both physical and psychological,...

Read More
CLINUVEL
Posted by CLINUVEL
December 20, 2021

CLINUVEL Communiqué VI

The last month has been a tragic lesson in the challenges posed...

Read More
CLINUVEL
Posted by CLINUVEL
November 24, 2021

CLINUVEL Kommuniqué V

CLINUVELs fünftes Nachrichtenkommuniqué für 2021. Bespricht EPP, klinisches Programm, IR-Update und mehr.

Read More
Lachlan Hay
Posted by Lachlan Hay
November 22, 2021

CLINUVEL Communiqué V

CLINUVEL’s fifth News Communiqué for 2021. Discusses EPP, clinical program, IR update...

Read More
CLINUVEL
Posted by CLINUVEL
November 18, 2021

CLINUVEL’S GROWTH AND EXPANSION - Jefferies London Healthcare Conference

CLINUVEL's Head of Investor Relations, Malcolm Bull, presents to the 2021 Jefferies...

Read More
CLINUVEL
Posted by CLINUVEL
November 10, 2021

Results of Annual General Meeting 2021

In accordance with Listing Rule 3.13.2 and section 251AA of the Corporations...

Read More
CLINUVEL
Posted by CLINUVEL
November 10, 2021

Chair Address

CLINUVEL PHARMACEUTICALS LTD today released its third Strategic Update.

Read More
CLINUVEL
Posted by CLINUVEL
November 10, 2021

CEO's Address - 2021 Annual General Meeting

2021 CLINUVEL Annual General Meeting address from CEO, Dr Philippe Wolgen

Read More
Lachlan Hay
Posted by Lachlan Hay
November 8, 2021

CLINUVEL Expands Pharmaceutical Portfolio

Melanocortin drug NEURACTHEL® (ACTH) added for neurological, endocrinological and degenerative disorders

Read More
We use cookies to give you the best experience.